Fuat Emre CANPOLAT, Mehmet BÜYÜKTİRYAKİ, Evrim Alyamac DİZDAR, Nilufer OKUR, Handan BEZİRGANOĞLU, Fatmanur SARI, Nurdan URAS, Şerife Suna OĞUZ

Postnatal hydrocortisone therapy for the treatment of bronchopulmonary dysplasia in very low birth weight infants

Aim: Corticosteroids are widely used to prevent and treat bronchopulmonary dysplasia (BPD) due to their strong anti-inflammatoryeffects. We aim to evaluate the outcomes of late onset systemic hydrocortisone (HC) therapy in very low birth weight infants withBPD.Material and Methods: The medical records of 706 preterm infants with gestational age ≤ 30 weeks over a 4-year period wereretrospectively reviewed. Infants who required invasive/noninvasive respiratory support or ≥ 30% oxygen due to BPD and weretreated with HC after the third postnatal week were included. The infants were divided into 3 groups according to respiratory supportat the beginning of the HC treatment: mechanical ventilation (MV), noninvasive ventilation (NIV), and free oxygen.Results: Seventy-six (11.9%) infants in our cohort received HC therapy. In the MV group, 83.3% of the infants were successfullyextubated after a median of 4 days (interquartile range [IQR], 2-8 days). In the NIV group, 83.9% of the infants required no longerrespiratory support after a median of 6 days (IQR, 3-16 days). In the free oxygen group, none of the infants needed supplementaloxygen after a median of 8 days (IQR, 6-12 days).Conclusion: Late HC therapy facilitates extubating without adverse short-term effects, reduces the need of invasive and noninvasiveventilation, and facilitates discharge without supplemental oxygen.

PDF

___

1. Davis PG, Thorpe K, Roberts R, et al. Trial Indomethacin Prophylaxis in Preterms Investigators: Evaluating ‘old’ definitions for the ‘new’ bronchopulmonary dysplasia. J Pediatr 2002;140:555-60.
2. Hentschel J, Berger TM, Tschopp A, et al. Populationbased study of bronchopulmonary dysplasia in very low birth weight infants in Switzerland. Eur J Pediatr 2005;164:292-7.
3. Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med 2001;163:1723-9.
4. WatterbergK. Evidence-based neonatal pharmacotherapy: postnatal corticosteroids. Clin Perinatol 2012;39:47-59.
5. Jobe AH. Postnatal corticosteroids for bronchopulmonary dysplasia. Clin Perinatol 2009; 36:177-88.
6. Aschner JL, Bancalari EH, McEvoy CT. Can We Prevent Bronchopulmonary Dysplasia? J Pediatr 2017;189:26- 30.
7. Doyle LW, Ehrenkranz RA, Halliday HL. Early (<8 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev 2014;5:CD001146.
8. Doyle LW, Ehrenkranz RA, Halliday HL. Late (>7 days) postnatal corticosteroids for chronic lung disease in preterm infants. Cochrane Database Syst Rev 2014;5:CD001145.
9. Yeh TF, Lin YJ, Huang CC, et al. Early dexamethasone therapy in preterm infants: a follow-up study. Pediatrics 1998;1015:7.
10. O’Shea TM, Kothadia JM, Klinepeter KL, et al. Randomized placebo-controlled trial of a 42-day tapering course of dexamethasone to reduce the duration of ventilator dependency in very low birth weight infants: outcome of study participants at 1-year adjusted age. Pediatrics 1999;104:15-21.
11. Walsh MC, Yao Q, Horbar JD, et al. Changes in the use of postnatal steroids for bronchopulmonary dysplasia in 3 large neonatal networks. Pediatrics 2006;118:1328-35.
12. Yoder BA, Harrison M, Clark RH. Time-related changes in steroid use and bronchopulmonary dysplasia in preterm infants. Pediatrics 2009;124:673-9.
13. Huang CC, Lin HR, Liang YC, et al. Effects of neonatal corticosteroid treatment on hippocampal synaptic function. Pediatric Research 2007;62:267-70.
14. van der Heide-Jalving M, Kamphuis PJ, van der Lann MJ, et al. Short- and long-term effects of neonatal glucocorticoid therapy: is hydrocortisone an alternative to dexamethasone? Acta Paediatr 2003;92:827-35.
15. Rademaker KJ, de Vries LS, Uiterwaal CS, et al. Postnatal hydrocortisone treatment for chronic lung disease in the preterm newborn and long-term neurodevelopmental follow-up. Arch Dis Child Fetal Neonatal Ed 2008;93:F58–63.
16. Watterberg KL, Gerdes JS, Cole CH, et al. Prophylaxis of early adrenal insufficiency to prevent bronchopulmonary dysplasia: a multicenter trial. Pediatrics 2004;114:1649-57.
17. Doyle LW, Ehrenkranz RA, Halliday HL. Postnatal hydrocortisone for preventing or treating bronchopulmonary dysplasia in preterm infants: a systematic review. Neonatology 2010;98:111-7.
18. Baud O, Maury L, Lebail F, et al. Effect of early low-dose hydrocortisone on survival without bronchopulmonary dysplasia in extremely preterminfants (PREMILOC): a doubleblind, placebo-controlled, multicentre, randomised trial. Lancet 2016;387:1827-36.
19. Baud O, Trousson C, Biran V, et al. Association between early low-dose hydrocortisone therapy in extremely preterm neonates and neurodevelopmental outcomes at 2 years of age. JAMA 2017;317:1329-37.
20. Onland W, De Jaegere AP, Offringa M, et al. Systemic corticosteroid regimens for prevention of bronchopulmonary dysplasia in preterm infants. Cochrane Database Syst Rev 2017;1:CD010941.
21. Halliday HL. Update on Postnatal Steroids. Neonatology 2017;111:415-22.
22. Virkud YV, Hornik CP, Benjamin DK, et al.Respiratory support for very low birth weight infants receiving dexamethasone. J Pediatr 2017;183:26-30.
23. Nuytten A, Behal H, Duhamel A, et al; EPICE Research Group: Evidence-based neonatal unit practices and determinants of postnatal corticosteroid-use in preterm births below 30 weeks GA in Europe: a population-based cohort study. PLoS One 2017;12:0170234.
24. Onland W, Offringa M, Cools F, et al. Systemic Hydrocortisone To Prevent Bronchopulmonary Dysplasia in preterm infants (the SToP-BPD study); a multicenter randomized placebo controlled trial. BMC Pediatr 2011;11:102.
25. Walsh MC, Wilson-Costello D, Zadell A, et al. Safety, reliability, and validity of a physiologic definition of bronchopulmonary dysplasia. J Perinatol 2003;23:451-6.
26. Oncel MY, Yurttutan S, Erdeve O, et al. Oral paracetamol versus oral ibuprofen in the management of patent ductus arteriosus in preterm infants: a randomized controlled trial. J Pediatr 2014;164:510-4.
27. Papile LA, Burstein J, Burstein R, et al. Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. J Pediatr 1978;92:529-33.
28. Bell MJ, Ternberg JL, Feigin RD, et al. Neonatal necrotizing enterocolitis: therapeutic decisions based upon clinical staging. Ann Surg 1978;187:1-7.
29. Section on Ophthalmology American Academy of Pediatrics, American Academy of Ophthalmology, American Association for Pediatric Ophthalmology and Strabismus. Screening examination of premature infants for retinopathy of prematurity. Pediatrics 2006;117:572-576.
30. Renault A, Patkaï J, Dassieu G, et al. Hydrocortisone use in ventilated extremely preterm infants decreased bronchopulmonary dysplasia with no effects on neurodevelopment after two years. Acta Paediatr 2016;105:1047-55.
31. Ben Said M, Hays S, Loys CM, et al. Postnatal steroids in extremely low birth weight infants: betamethasone or hydrocortisone? Acta Paediatr 2013;102:689-94.
32. Parikh NA, Kennedy KA, Lasky RE, et al. Pilot randomized trial of hydrocortisone in ventilatordependent extremely preterm infants: effects on regional brain volumes. J Pediatr 2013;162:685-90.
33. de Jong SE, Groenendaal F, van Bel F, et al. Pulmonary effects of neonatal hydrocortisone treatment in ventilator-dependent preterm infants. Int J Pediatr 2011;783893:7.
34. Rademaker KJ, Uiterwaal CS, Groenendaal F, et al. Neonatal hydrocortisone treatment: neurodevelopmental outcome and MRI at school age in preterm-born children. J Pediatr 2007;150:351-7.